Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis

Li-Wei Yap; Jesper Brok; Kathy Pritchard-Jones

doi:10.1080/15513815.2016.1256358

Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis

Li-Wei Yap, Jesper Brok, Kathy Pritchard-Jones

Afdeling for Børn og Unge

11 Citationer (Scopus)

Abstract

The cell-surface glycoprotein CD56 has three major isoforms that play important roles in cell adhesion and signaling, which may promote cell proliferation, differentiation, survival, or migration. It is an important molecule in normal kidney development and acts as a key marker in Wilms tumor stem and progenitor cells. Here, we review the structural and genetic features of the CD56 glycoprotein, and summarize its roles in the normal versus diseased metanephric blastema. We discuss areas of CD56-related research that may complement or improve existing Wilms tumor treatment strategies, including the antibody-drug conjugate lorvotuzumab mertansine that binds to CD56.

Originalsprog	Engelsk
Tidsskrift	Fetal and Pediatric Pathology (Print Edition)
Vol/bind	36
Udgave nummer	1
Sider (fra-til)	62-75
Antal sider	14
ISSN	1551-3815
DOI	https://doi.org/10.1080/15513815.2016.1256358
Status	Udgivet - feb. 2017

Adgang til dokumentet

10.1080/15513815.2016.1256358

Citationsformater

@article{9cee8fbb20f547fba3cc56380e64440c,

title = "Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis",

abstract = "The cell-surface glycoprotein CD56 has three major isoforms that play important roles in cell adhesion and signaling, which may promote cell proliferation, differentiation, survival, or migration. It is an important molecule in normal kidney development and acts as a key marker in Wilms tumor stem and progenitor cells. Here, we review the structural and genetic features of the CD56 glycoprotein, and summarize its roles in the normal versus diseased metanephric blastema. We discuss areas of CD56-related research that may complement or improve existing Wilms tumor treatment strategies, including the antibody-drug conjugate lorvotuzumab mertansine that binds to CD56.",

keywords = "Antibodies, Monoclonal, CD56 Antigen, Cell Adhesion, Cell Differentiation, Cell Movement, Cell Proliferation, Cell Survival, Glycoproteins, Humans, Kidney, Maytansine, Protein Binding, Protein Domains, Receptor, Fibroblast Growth Factor, Type 1, Signal Transduction, Wilms Tumor, Journal Article, Review",

author = "Li-Wei Yap and Jesper Brok and Kathy Pritchard-Jones",

year = "2017",

month = feb,

doi = "10.1080/15513815.2016.1256358",

language = "English",

volume = "36",

pages = "62--75",

journal = "Fetal and Pediatric Pathology (Print Edition)",

issn = "1551-3815",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis

AU - Yap, Li-Wei

AU - Brok, Jesper

AU - Pritchard-Jones, Kathy

PY - 2017/2

Y1 - 2017/2

N2 - The cell-surface glycoprotein CD56 has three major isoforms that play important roles in cell adhesion and signaling, which may promote cell proliferation, differentiation, survival, or migration. It is an important molecule in normal kidney development and acts as a key marker in Wilms tumor stem and progenitor cells. Here, we review the structural and genetic features of the CD56 glycoprotein, and summarize its roles in the normal versus diseased metanephric blastema. We discuss areas of CD56-related research that may complement or improve existing Wilms tumor treatment strategies, including the antibody-drug conjugate lorvotuzumab mertansine that binds to CD56.

AB - The cell-surface glycoprotein CD56 has three major isoforms that play important roles in cell adhesion and signaling, which may promote cell proliferation, differentiation, survival, or migration. It is an important molecule in normal kidney development and acts as a key marker in Wilms tumor stem and progenitor cells. Here, we review the structural and genetic features of the CD56 glycoprotein, and summarize its roles in the normal versus diseased metanephric blastema. We discuss areas of CD56-related research that may complement or improve existing Wilms tumor treatment strategies, including the antibody-drug conjugate lorvotuzumab mertansine that binds to CD56.

KW - Antibodies, Monoclonal

KW - CD56 Antigen

KW - Cell Adhesion

KW - Cell Differentiation

KW - Cell Movement

KW - Cell Proliferation

KW - Cell Survival

KW - Glycoproteins

KW - Humans

KW - Kidney

KW - Maytansine

KW - Protein Binding

KW - Protein Domains

KW - Receptor, Fibroblast Growth Factor, Type 1

KW - Signal Transduction

KW - Wilms Tumor

KW - Journal Article

KW - Review

U2 - 10.1080/15513815.2016.1256358

DO - 10.1080/15513815.2016.1256358

M3 - Review

C2 - 27935326

SN - 1551-3815

VL - 36

SP - 62

EP - 75

JO - Fetal and Pediatric Pathology (Print Edition)

JF - Fetal and Pediatric Pathology (Print Edition)

IS - 1

ER -

Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater